| Literature DB >> 34214667 |
Dalinda Eusébio1, Ana R Neves1, Diana Costa1, Swati Biswas2, Gilberto Alves1, Zhengrong Cui3, Ângela Sousa4.
Abstract
DNA vaccines have emerged as innovative approaches that have great potential to overcome the limitations of current conventional vaccines. Plasmid DNA vaccines are often safer than other vaccines because they carry only antigen genetic information, are more stable and easier to produce, and can stimulate both humoral and cellular immune responses. Although the results of ongoing clinical trials are very promising, some limitations compromise the immunogenicity of these vaccines. Thus, this review describes different strategies that can be explored to improve the immunogenicity of plasmid DNA vaccines, including the optimization of the plasmid vector backbone, the use of different methods for vaccine delivery, the use of alternative administration routes and the inclusion of adjuvants. In combination, these improvements could lead to the successful clinical use of plasmid DNA vaccines.Entities:
Keywords: Adjuvants; Administration routes; Delivery systems; Immunogenicity; Plasmid DNA vaccines
Mesh:
Substances:
Year: 2021 PMID: 34214667 DOI: 10.1016/j.drudis.2021.06.008
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851